

Senate Bill 626

Sponsored by Senators KRUSE, BATES, MONNES ANDERSON

SUMMARY

The following summary is not prepared by the sponsors of the measure and is not a part of the body thereof subject to consideration by the Legislative Assembly. It is an editor's brief statement of the essential features of the measure **as introduced**.

Allows additional persons to access information from prescription monitoring program.
Requires practitioners to access information from program before prescribing or dispensing prescription drugs classified in schedules II through IV. Creates exceptions.
Becomes operative January 1, 2016.
Declares emergency, effective on passage.

A BILL FOR AN ACT

1
2 Relating to prescription drugs; creating new provisions; amending ORS 431.966; and declaring an
3 emergency.

4 **Be It Enacted by the People of the State of Oregon:**

5 **SECTION 1.** ORS 431.966 is amended to read:

6 431.966. (1)(a) Except as provided under subsection (2) of this section, prescription monitoring
7 information submitted under ORS 431.964 to the prescription monitoring program established in ORS
8 431.962:

9 (A) Is protected health information under ORS 192.553 to 192.581.

10 (B) Is not subject to disclosure pursuant to ORS 192.410 to 192.505.

11 (b) Except as provided under subsection [(2)(a)(E)] **(2)(a)(G)** of this section, prescription moni-
12 toring information submitted under ORS 431.964 to the prescription monitoring program may not be
13 used to evaluate a practitioner's professional practice.

14 (2)(a) To the extent that the law or regulation is applicable to the prescription monitoring pro-
15 gram, if a disclosure of prescription monitoring information, other than the sex of a patient for
16 whom a drug was prescribed, complies with the federal Health Insurance Portability and Account-
17 ability Act of 1996 (P.L. 104-191) and regulations adopted under it, including 45 C.F.R. parts 160
18 and 164, federal alcohol and drug treatment confidentiality laws and regulations [*adopted under those*
19 *laws*], including 42 C.F.R. part 2, and state health and mental health confidentiality laws, including
20 ORS 179.505, 192.517 and 192.553 to 192.581, the Oregon Health Authority shall disclose the infor-
21 mation:

22 (A) To a practitioner or pharmacist, or, if a practitioner or pharmacist authorizes the authority
23 to disclose the information to a member of the practitioner's or pharmacist's staff, to a member of
24 the practitioner's or pharmacist's staff. If a practitioner or pharmacist authorizes disclosing the in-
25 formation to a member of the practitioner's or pharmacist's staff under this subparagraph, the
26 practitioner or pharmacist remains responsible for the use or misuse of the information by the staff
27 member. To receive information under this subparagraph, or to authorize the receipt of information
28 by a staff member under this subparagraph, a practitioner or pharmacist must certify that the re-
29 quested information is for the purpose of evaluating the need for or providing medical or pharma-
30 ceutical treatment [*for*] **to** a patient to whom the practitioner or pharmacist anticipates providing,

NOTE: Matter in **boldfaced** type in an amended section is new; matter [*italic and bracketed*] is existing law to be omitted.
New sections are in **boldfaced** type.

1 is providing or has provided care.

2 **(B) To a practitioner or pharmacist as part of an automated system integrated into the**
 3 **prescription monitoring program by the authority. An automated system integrated into the**
 4 **prescription monitoring program under this subparagraph may disclose information only for**
 5 **the purposes of notifying a practitioner or pharmacist of a potentially dangerous drug**
 6 **interaction or of multiple practitioners prescribing drugs to a patient.**

7 [(B)] (C) To a practitioner in a form that catalogs all prescription drugs prescribed by the
 8 practitioner according to the number assigned to the practitioner by the Drug Enforcement Admin-
 9 istration of the United States Department of Justice.

10 **(D) To a district or county health officer appointed, employed or under contract as de-**
 11 **scribed in ORS 431.418.**

12 [(C)] (E) To designated representatives of the authority or any vendor or contractor with whom
 13 the authority has contracted to establish or maintain the electronic system of the prescription
 14 monitoring program.

15 [(D)] (F) Pursuant to a valid court order based on probable cause and issued at the request of
 16 a federal, state or local law enforcement agency engaged in an authorized drug-related investigation
 17 involving a person to whom the requested information pertains.

18 [(E)] (G) To a health professional regulatory board that certifies in writing that the requested
 19 information is necessary for an investigation related to licensure, **licensure** renewal or a discipli-
 20 nary action involving the applicant, licensee or registrant to whom the requested information per-
 21 tains.

22 **(H) To the State Medical Examiner or designee of the State Medical Examiner, a district**
 23 **medical examiner appointed under ORS 146.065 or a deputy medical examiner appointed under**
 24 **ORS 146.085, for the purpose of conducting a medicolegal investigation or autopsy.**

25 **(I) Upon request, and in accordance with rules adopted by the authority, to a person to**
 26 **whom information is disclosed under paragraph (b)(A) or (c) of this subsection for the pur-**
 27 **pose of comparing information kept in different databases, provided that the person to whom**
 28 **the information is disclosed does not publish or otherwise disclose any information that**
 29 **identifies a patient, practitioner or drug outlet.**

30 [(F)] (J) To a prescription monitoring program of another state if the confidentiality, security
 31 and privacy standards of the requesting state are determined by the authority to be equivalent to
 32 those of the authority.

33 [(G) *To the State Medical Examiner or designee of the State Medical Examiner, for the purpose*
 34 *of conducting a medicolegal investigation or autopsy.*]

35 (b) The authority may disclose information from the prescription monitoring program that does
 36 not identify a patient, practitioner or drug outlet:

37 (A) For educational, research or public health purposes;

38 (B) To a local public health authority, as defined in ORS 431.260; or

39 (C) To officials of the authority who are conducting special epidemiologic morbidity and mor-
 40 tality studies in accordance with ORS 413.196 and rules adopted under ORS 431.110.

41 **(c) A local public health authority, as defined in ORS 431.260, may disclose information**
 42 **from the prescription monitoring program that does not identify a patient, practitioner or**
 43 **drug outlet for educational, research or public health purposes.**

44 [(c)] (d) The authority shall disclose information relating to a patient maintained in the elec-
 45 tronic system operated pursuant to the prescription monitoring program [*established under ORS*

1 431.962] to that patient at no cost to the patient within 10 business days after the authority receives
2 a request from the patient for the information.

3 [(d)(A)] (e)(A) A patient may request the authority to correct any information about the patient
4 that is erroneous. The authority shall grant or deny a request to correct information within 10
5 business days after the authority receives the request.

6 (B) If the authority denies a patient's request to correct information under this paragraph, or
7 fails to grant a patient's request to correct information under this paragraph within 10 business days
8 after the authority receives the request, the patient may appeal the denial or failure to grant the
9 request. Upon [receipt] **receiving notice** of an appeal under this subparagraph, the authority shall
10 conduct a contested case hearing as provided in ORS chapter 183. Notwithstanding ORS 183.450,
11 [in the contested case hearing,] the authority has the burden **in the contested case hearing** of es-
12 tablishing that the information included in the prescription monitoring program is correct.

13 [(e)] (f) The information in the prescription monitoring program may not be used for any com-
14 mercial purpose.

15 [(f)] (g) In accordance with ORS 192.553 to 192.581 and federal privacy regulations, any person
16 authorized to prescribe or dispense a prescription drug and who is entitled to access a patient's
17 prescription monitoring information may discuss or release the information to other health care
18 providers involved with the patient's care[, in order to provide] **for the purpose of providing** safe
19 and appropriate care coordination.

20 (3)(a) The authority shall maintain records of the information disclosed through the prescription
21 monitoring program including, but not limited to:

22 (A) The identity of each person who requests or receives information from the program and [the
23 organization, if any,] **any organization that** the person represents;

24 (B) The information released to each person or organization; and

25 (C) The date and time the information was requested and the date and time the information was
26 provided.

27 (b) Records maintained as required by this subsection may be reviewed by the Prescription
28 Monitoring Program Advisory Commission.

29 (4) Information in the prescription monitoring program that identifies an individual patient must
30 be removed no later than three years from the date the information is entered into the program.

31 (5) The authority shall notify the Attorney General and each affected individual of an improper
32 disclosure of information from the prescription monitoring program.

33 (6)(a) If the authority or a person or entity required to report or authorized to receive or release
34 controlled substance prescription information under this section violates this section or ORS 431.964
35 or 431.968, a person injured by the violation may bring a civil action against the authority, person
36 or entity and may recover damages in the amount of \$1,000 or actual damages, whichever is greater.

37 (b) Notwithstanding paragraph (a) of this subsection, the authority and a person or entity re-
38 quired to report or authorized to receive or release controlled substance prescription information
39 under this section are immune from civil liability for violations of this section or ORS 431.964 or
40 431.968 unless the authority, person or entity acts with malice, criminal intent, gross negligence,
41 recklessness or willful intent.

42 (7) [Nothing in ORS 431.962 to 431.978 and 431.992 requires a practitioner or pharmacist who
43 prescribes or dispenses a prescription drug to obtain information about a patient from the prescription
44 monitoring program.] A practitioner or pharmacist who prescribes or dispenses a prescription drug
45 may not be held liable for damages in any civil action on the basis that the practitioner or

1 pharmacist [*did or did not request or obtain*] **requested or obtained** information from the pre-
2 scription monitoring program.

3 **SECTION 2.** Sections 3 and 4 of this 2015 Act are added to and made a part of ORS 431.962
4 to 431.978.

5 **SECTION 3.** (1) Except as provided in subsection (2) of this section, a practitioner shall
6 access information from the prescription monitoring program established under ORS 431.962
7 as described in ORS 431.966 (2)(a)(A) before the practitioner prescribes or dispenses to a pa-
8 tient a prescription drug that is classified in schedules II through IV.

9 (2) This section does not apply to:

10 (a) A practitioner described in ORS 431.960 (4)(b).

11 (b) A veterinarian.

12 (c) A practitioner administering a prescription drug.

13 (d) A practitioner prescribing or dispensing a prescription drug at a health care facility,
14 as defined in ORS 442.015, for use on the premises of the health care facility.

15 (e) A practitioner prescribing or dispensing a prescription drug to a recipient of hospice
16 services, as defined in ORS 443.850.

17 (f) A practitioner dispensing methadone or buprenorphine for purposes related to opioid
18 addition therapy.

19 (g) A practitioner to whom a waiver has been granted under subsection (3) of this sec-
20 tion.

21 (h) All practitioners if the prescription monitoring program is inaccessible because the
22 electronic system described in ORS 431.962 is inoperable.

23 (3) The authority may grant a practitioner a waiver of the requirement to access infor-
24 mation from the prescription monitoring program under this section for good cause as de-
25 termined by the authority. For purposes of this subsection, good cause includes insufficient
26 technological resources necessary to access the information.

27 **SECTION 4.** (1) In addition to any other penalty provided by law, a health professional
28 regulatory board:

29 (a) May suspend, revoke or refuse to renew a license or registration of a licensee or
30 registrant of the health professional regulatory board who violates section 3 of this 2015 Act;
31 and

32 (b) May impose on a licensee or registrant of the health professional regulatory board a
33 civil penalty not to exceed \$1,000 for each violation of section 3 of this 2015 Act that is
34 committed by the licensee or registrant.

35 (2) Each failure to access information from the prescription monitoring program estab-
36 lished under ORS 431.962 is a separate violation.

37 (3) A health professional regulatory board shall impose a civil penalty under this section
38 in the manner provided in ORS 183.745.

39 (4) A health professional regulatory board may adopt rules necessary to carry out the
40 provisions of this section.

41 (5) Moneys recovered under this section must be paid into the State Treasury and cred-
42 ited to the General Fund.

43 **SECTION 5.** The amendments to ORS 431.966 by section 1 of this 2015 Act apply to in-
44 formation related to prescription drugs classified in schedules II through IV that are dis-
45 pensed before, on or after the operative date specified in section 6 of this 2015 Act.

